Opinion

Video

Conditions for Administering Bispecific Therapy

Experts explore optimal conditions for effective bispecific therapy in an insightful panel discussion.

The following is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA, CPEL; Kirollos Hanna, PharmD, BCPS, BCOP, FACCC; Sarah Rockwell, PharmD, BCOP; Melody Chang, RPh, MBA, BCOP; and Ryan Cain, PA-C.

The video discusses considerations for operationalizing bispecific monoclonal antibodies in cancer care. It highlights the importance of having protocols in place for patient monitoring, transition of care, risk evaluation and mitigation strategies programs, management of adverse events like cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome, and long-term toxicity monitoring. Key factors include setting patient eligibility criteria, caregiver reliability for adherence, transportation to handle severe adverse effects, and financial considerations for insurance authorizations. As these are continuous therapies, extensive plans must be made to support patients across the entirety of their treatment journey.

Video synopsis is AI-generated and reviewed by AJMC editorial staff.

Related Videos
Justin Oldham, MD, MS, an expert on IPF
Ruben Mesa, MD
Amit Garg, MD, Northwell Health
4 KOLs are featured in this series
4 KOLs are featured in this series
Surbhi Sidana, MD, MBBS
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo